3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
5
NIH
4
NETWORK
3
INDUSTRY
3
OTHER_GOV
1
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Interventions
Bevacizumab
4
Zoledronic Acid
3
Cisplatin
3
Capecitabine
3
spartalizumab
2
anlotinib
2
Radiotherapy
2
Positron Emission Tomography Computed Tomography
2
Metformin
2
Letrozole
2
Drug Therapy
2
vosaroxin
1
venetoclax
1
tislelizumab
1
pembrolizumab
1
enzalutamide
1
empagliflozin
1
atezolizumab
1
apatinib
1
abiraterone
1
XELOX
1
Vacuum Curettage
1
Tyrosine Kinase Inhibitors
1
Tuberculin
1
Sorafenib
1
Sodium Chloride
1
S 1 (combination)
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
OTHER_GOV
×
Prednisone
×
Clear all
NCT00268476
2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3
Active not recruiting
11,992 enrolled